Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
Pharma & Biotech

Cryo-Cell avoided a delisting scare for now, but investors still face a 2027 countdown

Cryo-Cell avoided immediate delisting pressure. The harder test is whether its cord blood banking model can repair the balance sheet by 2027.

Read More
Representative image: Ensoma’s EN-374 clinical safety data highlight the growing promise of in vivo hematopoietic stem cell engineering for X-linked chronic granulomatous disease, as gene therapy developers test whether one-time treatments can move beyond complex ex vivo manufacturing and into scalable clinical use.
Pharma & Biotech

Ensoma’s EN-374 safety data open a new test for in vivo HSC engineering

In vivo gene therapy has reached human HSC engineering. Ensoma’s EN-374 safety data raise a bigger question: can durability follow?

Read More
Representative image: Kanvas Biosciences’ Gates Foundation-backed microbiome therapy program highlights how synthetic live biotherapeutics could target maternal environmental enteric dysfunction, a gut disorder linked to undernutrition, low birthweight and newborn health risks in Southern Asia and Sub-Saharan Africa.
Pharma & Biotech

Can Kanvas Biosciences turn microbiome replacement into a maternal health intervention?

Maternal EED lacks scalable therapies. Kanvas Biosciences now faces the harder test: proving microbiome replacement can work where need is greatest.

Read More
Representative image: A pediatric neurology research setting highlights the clinical and regulatory stakes behind Actio Biosciences’ KYRON trial of ABS-1230 for KCNT1-related epilepsy, as precision medicine developers seek new treatment pathways for ultra-rare genetic seizure disorders.
Pharma & Biotech

Could Actio’s KCNT1 epilepsy drug become an ultra-rare disease test case for the FDA?

Ultra-rare epilepsy has few paths forward. Actio’s ABS-1230 now tests whether precision genetics can reshape FDA evidence standards.

Read More
Pharma & Biotech

How Zifo’s AI authoring platform could reshape clinical and CMC documentation

Regulatory teams need speed, but AI needs auditability. Zifo’s authoring platform tests whether pharma can have both.

Read More
Representative image: INOVIO Pharmaceuticals’ upcoming ASCO and ASGCT conference posters place INO-3107 DNA immunotherapy and early hemophilia A gene transfer research under the spotlight as investors watch the biotech firm’s regulatory and platform strategy.
Pharma & Biotech

INOVIO’s ASCO and ASGCT updates may sharpen scrutiny of its DNA medicine strategy

INOVIO has a regulatory clock ticking. New INO-3107 and hemophilia A data may show whether its DNA platform can move beyond promise.

Read More
Pharma & Biotech

Pharma has a Hispanic engagement problem. Relevant+ thinks Healthy Vibras can fix it

Hispanic health trust is still uneven. Healthy Vibras tests whether culture-first media can change pharma engagement.

Read More
Representative image: Soligenix’s HyBryte trial setback has shifted investor and industry attention toward rare disease pipeline priorities, cash runway, and the future of SGX945 in Behçet’s disease.
Pharma & Biotech

What Soligenix’s Q1 update reveals about biotech risk after a failed confirmatory trial

HyBryte’s setback leaves Soligenix with cash, orphan assets, and a harder question. Can SGX945 reset the rare disease story?

Read More
Representative image of a biopharmaceutical laboratory workflow showing HEK293 functional cell line research, assay development and compliance documentation, as ACROBiosystems streamlines global licensing access to support faster drug discovery and regulated R&D operations.
Pharma & Biotech

ACROBiosystems makes HEK293 functional cell lines easier to use in global R&D workflows

HEK293 tools are everywhere, but licensing slows teams down. ACROBiosystems is turning compliance clarity into an R&D advantage.

Read More
Representative image of berberine-infused natural GLP-1 supplements with botanical ingredients and healthy food cues, reflecting PureHealth Research’s push into metabolic wellness, satiety support, and the fast-growing consumer health market for natural GLP-1 alternatives.
Pharma & Biotech

Why PureHealth Research’s berberine GLP-1 supplement push enters a crowded evidence debate

GLP-1 demand is reshaping supplements. PureHealth Research’s berberine launch tests where wellness claims meet evidence and regulation.

Read More